RxDoctor Payments Data

Isaac Omoloyin

Psychiatric/Mental Health · Wayne, NJNPI 1770038788

Payments from drug & device makers

$2,122in general payments, 2019–2025

Across 134 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$539
  • Otsuka America Pharmaceutical, Inc.$392
  • Johnson & Johnson$386
  • Teva Pharmaceuticals USA, Inc.$342
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$271
  • Neurelis, Inc.$92
  • plus $99 from 2 others

What the payments were for

  • Food & beverage$1,92691%
  • Education$1959%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,122 in reported general payments places this provider in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

See all psychiatric/mental health providers in New Jersey

Medicare billing

Part B allowed, 2024
$463,468
Medicare patients
1,924
Services billed
7,485

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate34$249,517
Invega SustennaPaliperidone Palmitate92$220,551
Abilify MaintenaAripiprazole65$180,373
Invega TrinzaPaliperidone Palmitate12$50,856
Clozapine325$46,508
Risperdal ConstaRisperidone Microspheres25$29,532
Risperidone ErRisperidone Microspheres22$23,327
Divalproex Sodium527$19,076
Lorazepam979$16,222
Clonazepam988$14,910
Buspirone Hcl416$10,538
Mirtazapine293$10,188
Alprazolam571$5,672
BelsomraSuvorexant35$5,590
Olanzapine157$4,216

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta$386$300,939129 claims
Neurocrine Biosciences, Inc.Ingrezza$539$249,51734 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$392$180,37365 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,212 psychiatric/mental health providers in New Jersey.

Other psychiatric/mental health in Wayne

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →